195 related articles for article (PubMed ID: 38437557)
21. Transcriptional control of the MUC16 promoter facilitates follicle-stimulating hormone peptide-conjugated shRNA nanoparticle-mediated inhibition of ovarian carcinoma in vivo.
Zhang MX; Hong SS; Cai QQ; Zhang M; Chen J; Zhang XY; Xu CJ
Drug Deliv; 2018 Nov; 25(1):797-806. PubMed ID: 29542355
[TBL] [Abstract][Full Text] [Related]
22. SMARCE1 regulates metastatic potential of breast cancer cells through the HIF1A/PTK2 pathway.
Sethuraman A; Brown M; Seagroves TN; Wu ZH; Pfeffer LM; Fan M
Breast Cancer Res; 2016 Aug; 18(1):81. PubMed ID: 27495308
[TBL] [Abstract][Full Text] [Related]
23. Delivery of Therapeutics Targeting the mRNA-Binding Protein HuR Using 3DNA Nanocarriers Suppresses Ovarian Tumor Growth.
Huang YH; Peng W; Furuuchi N; Gerhart J; Rhodes K; Mukherjee N; Jimbo M; Gonye GE; Brody JR; Getts RC; Sawicki JA
Cancer Res; 2016 Mar; 76(6):1549-59. PubMed ID: 26921342
[TBL] [Abstract][Full Text] [Related]
24. Lipid Nanoparticle Technology for Clinical Translation of siRNA Therapeutics.
Kulkarni JA; Witzigmann D; Chen S; Cullis PR; van der Meel R
Acc Chem Res; 2019 Sep; 52(9):2435-2444. PubMed ID: 31397996
[TBL] [Abstract][Full Text] [Related]
25. Cytoplasmic expression of EGFR shRNA using a modified T7 autogene-based hybrid mRNA/DNA system induces long-term EGFR silencing and prolongs antitumor effects.
Seraj S; Cho YJ; Lee JW; Ahn HJ
Biochem Pharmacol; 2020 Jan; 171():113735. PubMed ID: 31786264
[TBL] [Abstract][Full Text] [Related]
26. Tumor-targeted inhibition by a novel strategy - mimoretrovirus expressing siRNA targeting the Pokemon gene.
Tian Z; Wang H; Jia Z; Shi J; Tang J; Mao L; Liu H; Deng Y; He Y; Ruan Z; Li J; Wu Y; Ni B
Curr Cancer Drug Targets; 2010 Dec; 10(8):932-41. PubMed ID: 20879980
[TBL] [Abstract][Full Text] [Related]
27. Targeting SOD1 via RNAi with PEGylated graphene oxide nanoparticles in platinum-resistant ovarian cancer.
Szénási A; Sivasudhan E; Du H; Zhang P; Huang J; Zhang Z; Rocha S; Wang M
Cancer Gene Ther; 2023 Nov; 30(11):1554-1568. PubMed ID: 37582934
[TBL] [Abstract][Full Text] [Related]
28. Microfluidic Assembly of siRNA-Loaded Micelleplexes for Tumor Targeting in an Orthotopic Model of Ovarian Cancer.
Feldmann DP; Jones S; Douglas K; Shields AF; Merkel OM
Methods Mol Biol; 2019; 1974():355-369. PubMed ID: 31099014
[TBL] [Abstract][Full Text] [Related]
29. Cosilencing of PKM-2 and MDR-1 Sensitizes Multidrug-Resistant Ovarian Cancer Cells to Paclitaxel in a Murine Model of Ovarian Cancer.
Talekar M; Ouyang Q; Goldberg MS; Amiji MM
Mol Cancer Ther; 2015 Jul; 14(7):1521-31. PubMed ID: 25964202
[TBL] [Abstract][Full Text] [Related]
30. SiRNA and epigenetic aberrations in ovarian cancer.
Mirzaei H; Yazdi F; Salehi R; Mirzaei HR
J Cancer Res Ther; 2016; 12(2):498-508. PubMed ID: 27461600
[TBL] [Abstract][Full Text] [Related]
31. Nanoparticulate RNA delivery systems in cancer.
Sharma A; Jha NK; Dahiya K; Singh VK; Chaurasiya K; Jha AN; Jha SK; Mishra PC; Dholpuria S; Astya R; Nand P; Kumar A; Ruokolainen J; Kesari KK
Cancer Rep (Hoboken); 2020 Oct; 3(5):e1271. PubMed ID: 32729987
[TBL] [Abstract][Full Text] [Related]
32. DNA vector-based RNA interference to study gene function in cancer.
Stovall DB; Wan M; Zhang Q; Dubey P; Sui G
J Vis Exp; 2012 Jun; (64):e4129. PubMed ID: 22710444
[TBL] [Abstract][Full Text] [Related]
33. Biocompatible AIEgen/p-glycoprotein siRNA@reduction-sensitive paclitaxel polymeric prodrug nanoparticles for overcoming chemotherapy resistance in ovarian cancer.
Wu J; Wang Q; Dong X; Xu M; Yang J; Yi X; Chen B; Dong X; Wang Y; Lou X; Xia F; Wang S; Dai J
Theranostics; 2021; 11(8):3710-3724. PubMed ID: 33664857
[TBL] [Abstract][Full Text] [Related]
34. Long noncoding RNA HOTTIP promotes the metastatic potential of ovarian cancer through the regulation of the miR-615-3p/SMARCE1 pathway.
Wu H; Wei HY; Chen QQ
Kaohsiung J Med Sci; 2020 Dec; 36(12):973-982. PubMed ID: 32783402
[TBL] [Abstract][Full Text] [Related]
35. siRNA-Conjugated Nanoparticles to Treat Ovarian Cancer.
Halbur C; Choudhury N; Chen M; Kim JH; Chung EJ
SLAS Technol; 2019 Apr; 24(2):137-150. PubMed ID: 30616494
[TBL] [Abstract][Full Text] [Related]
36. Theranostic Nanoparticles for RNA-Based Cancer Treatment.
Revia RA; Stephen ZR; Zhang M
Acc Chem Res; 2019 Jun; 52(6):1496-1506. PubMed ID: 31135134
[TBL] [Abstract][Full Text] [Related]
37. Efficient siRNA delivery and tumor accumulation mediated by ionically cross-linked folic acid-poly(ethylene glycol)-chitosan oligosaccharide lactate nanoparticles: for the potential targeted ovarian cancer gene therapy.
Li TS; Yawata T; Honke K
Eur J Pharm Sci; 2014 Feb; 52():48-61. PubMed ID: 24178005
[TBL] [Abstract][Full Text] [Related]
38. Polymeric nanoparticles-siRNA as an emerging nano-polyplexes against ovarian cancer.
Rehman U; Parveen N; Sheikh A; Abourehab MAS; Sahebkar A; Kesharwani P
Colloids Surf B Biointerfaces; 2022 Oct; 218():112766. PubMed ID: 35994990
[TBL] [Abstract][Full Text] [Related]
39. First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement.
Tabernero J; Shapiro GI; LoRusso PM; Cervantes A; Schwartz GK; Weiss GJ; Paz-Ares L; Cho DC; Infante JR; Alsina M; Gounder MM; Falzone R; Harrop J; White AC; Toudjarska I; Bumcrot D; Meyers RE; Hinkle G; Svrzikapa N; Hutabarat RM; Clausen VA; Cehelsky J; Nochur SV; Gamba-Vitalo C; Vaishnaw AK; Sah DW; Gollob JA; Burris HA
Cancer Discov; 2013 Apr; 3(4):406-17. PubMed ID: 23358650
[TBL] [Abstract][Full Text] [Related]
40. Knockdown of RAB25 expression by RNAi inhibits growth of human epithelial ovarian cancer cells in vitro and in vivo.
Fan Y; Xin XY; Chen BL; Ma X
Pathology; 2006 Dec; 38(6):561-7. PubMed ID: 17393986
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
